• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300966.SZ
Share

Hubei Goto Biopharm Group Co., Ltd. Stocks

CN¥ 25.34Last Updated 20.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

CN¥ 443.39M

CN¥ 25.34
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hubei Goto Biopharm Co.,Ltd. is a Chinese enterprise specializing in the manufacture and distribution of active pharmaceutical ingredients (APIs) and intermediate compounds for steroid hormones. Its product line features essential starting materials such as 9a-hydroxy-4-androstenedione (9a-OHAD), bisnoralcohol (BA), sitolactone, 1,4-androstadienedione (ADD), and 4-androstenedione (4-AD). The company also provides a variety of intermediates, including those for estrogens, progesterone, non-steroidal substances, various other hormones, and corticosteroids. Furthermore, Hubei Goto Biopharm supplies additional raw materials for the pharmaceutical industry. The firm was established in Yicheng, China, in 2006.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.07.2026 19:15

Neuronetics, a company that develops treatments for depression, saw its stock price rise by 25%. What happened?

21.07.2026 18:54

The U.S. president may impose new tariffs on dozens of countries this week — FT

21.07.2026 18:18

Chinese AI models have caught up with their American counterparts. Will Beijing now restrict access to them?

21.07.2026 17:58

The Houthis have threatened to attack any ships that enter Saudi Arabian ports

21.07.2026 17:37

Kazakhstan to Suspend Oil Shipments to Its Main Export Terminal — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026